Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021

Background - Global evaluations of the progress towards the WHO End TB Strategy 2020 interim milestones on mortality (35% reduction) and incidence (20% reduction) have not been age specific. We aimed to assess global, regional, and national-level burdens of and trends in tuberculosis and its risk fa...

Full description

Saved in:
Bibliographic Details
Main Authors: Ledesma, Jorge R. (Author) , Al-Ahdal, Tareq (Author) , Jonas, Jost B. (Author) , Moazen, Babak (Author)
Format: Article (Journal)
Language:English
Published: July 2024
In: The lancet. Infectious diseases
Year: 2024, Volume: 24, Issue: 7, Pages: 698-725
ISSN:1474-4457
DOI:10.1016/S1473-3099(24)00007-0
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/S1473-3099(24)00007-0
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S1473309924000070
Get full text
Author Notes:Jorge R. Ledesma, Tareq Mohammed Ali AL-Ahdal, Jost B Jonas, Babak Moazen [und andere]

MARC

LEADER 00000caa a2200000 c 4500
001 1919709061
003 DE-627
005 20250717001023.0
007 cr uuu---uuuuu
008 250313s2024 xx |||||o 00| ||eng c
024 7 |a 10.1016/S1473-3099(24)00007-0  |2 doi 
035 |a (DE-627)1919709061 
035 |a (DE-599)KXP1919709061 
035 |a (OCoLC)1528019701 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Ledesma, Jorge R.  |e VerfasserIn  |0 (DE-588)125500729X  |0 (DE-627)1797782010  |4 aut 
245 1 0 |a Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy  |b a systematic analysis for the Global Burden of Disease Study 2021  |c Jorge R. Ledesma, Tareq Mohammed Ali AL-Ahdal, Jost B Jonas, Babak Moazen [und andere] 
264 1 |c July 2024 
300 |b Illustrationen 
300 |a 28 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online verfügbar: 19. März 2024, Artikelversion: 19. Juni 2024 
500 |a Gesehen am 13.03.2025 
520 |a Background - Global evaluations of the progress towards the WHO End TB Strategy 2020 interim milestones on mortality (35% reduction) and incidence (20% reduction) have not been age specific. We aimed to assess global, regional, and national-level burdens of and trends in tuberculosis and its risk factors across five separate age groups, from 1990 to 2021, and to report on age-specific progress between 2015 and 2020. - Methods - We used the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 (GBD 2021) analytical framework to compute age-specific tuberculosis mortality and incidence estimates for 204 countries and territories (1990-2021 inclusive). We quantified tuberculosis mortality among individuals without HIV co-infection using 22 603 site-years of vital registration data, 1718 site-years of verbal autopsy data, 825 site-years of sample-based vital registration data, 680 site-years of mortality surveillance data, and 9 site-years of minimally invasive tissue sample (MITS) diagnoses data as inputs into the Cause of Death Ensemble modelling platform. Age-specific HIV and tuberculosis deaths were established with a population attributable fraction approach. We analysed all available population-based data sources, including prevalence surveys, annual case notifications, tuberculin surveys, and tuberculosis mortality, in DisMod-MR 2.1 to produce internally consistent age-specific estimates of tuberculosis incidence, prevalence, and mortality. We also estimated age-specific tuberculosis mortality without HIV co-infection that is attributable to the independent and combined effects of three risk factors (smoking, alcohol use, and diabetes). As a secondary analysis, we examined the potential impact of the COVID-19 pandemic on tuberculosis mortality without HIV co-infection by comparing expected tuberculosis deaths, modelled with trends in tuberculosis deaths from 2015 to 2019 in vital registration data, with observed tuberculosis deaths in 2020 and 2021 for countries with available cause-specific mortality data. - Findings - We estimated 9·40 million (95% uncertainty interval [UI] 8·36 to 10·5) tuberculosis incident cases and 1·35 million (1·23 to 1·52) deaths due to tuberculosis in 2021. At the global level, the all-age tuberculosis incidence rate declined by 6·26% (5·27 to 7·25) between 2015 and 2020 (the WHO End TB strategy evaluation period). 15 of 204 countries achieved a 20% decrease in all-age tuberculosis incidence between 2015 and 2020, eight of which were in western sub-Saharan Africa. When stratified by age, global tuberculosis incidence rates decreased by 16·5% (14·8 to 18·4) in children younger than 5 years, 16·2% (14·2 to 17·9) in those aged 5-14 years, 6·29% (5·05 to 7·70) in those aged 15-49 years, 5·72% (4·02 to 7·39) in those aged 50-69 years, and 8·48% (6·74 to 10·4) in those aged 70 years and older, from 2015 to 2020. Global tuberculosis deaths decreased by 11·9% (5·77 to 17·0) from 2015 to 2020. 17 countries attained a 35% reduction in deaths due to tuberculosis between 2015 and 2020, most of which were in eastern Europe (six countries) and central Europe (four countries). There was variable progress by age: a 35·3% (26·7 to 41·7) decrease in tuberculosis deaths in children younger than 5 years, a 29·5% (25·5 to 34·1) decrease in those aged 5-14 years, a 15·2% (10·0 to 20·2) decrease in those aged 15-49 years, a 7·97% (0·472 to 14·1) decrease in those aged 50-69 years, and a 3·29% (-5·56 to 9·07) decrease in those aged 70 years and older. Removing the combined effects of the three attributable risk factors would have reduced the number of all-age tuberculosis deaths from 1·39 million (1·28 to 1·54) to 1·00 million (0·703 to 1·23) in 2020, representing a 36·5% (21·5 to 54·8) reduction in tuberculosis deaths compared to those observed in 2015. 41 countries were included in our analysis of the impact of the COVID-19 pandemic on tuberculosis deaths without HIV co-infection in 2020, and 20 countries were included in the analysis for 2021. In 2020, 50 900 (95% CI 49 700 to 52 400) deaths were expected across all ages, compared to an observed 45 500 deaths, corresponding to 5340 (4070 to 6920) fewer deaths; in 2021, 39 600 (38 300 to 41 100) deaths were expected across all ages compared to an observed 39 000 deaths, corresponding to 657 (-713 to 2180) fewer deaths. - Interpretation - Despite accelerated progress in reducing the global burden of tuberculosis in the past decade, the world did not attain the first interim milestones of the WHO End TB Strategy in 2020. The pace of decline has been unequal with respect to age, with older adults (ie, those aged >50 years) having the slowest progress. As countries refine their national tuberculosis programmes and recalibrate for achieving the 2035 targets, they could consider learning from the strategies of countries that achieved the 2020 milestones, as well as consider targeted interventions to improve outcomes in older age groups. - Funding - Bill & Melinda Gates Foundation. 
700 1 |a Al-Ahdal, Tareq  |d 1990-  |e VerfasserIn  |0 (DE-588)127846140X  |0 (DE-627)1831330547  |4 aut 
700 1 |a Jonas, Jost B.  |d 1958-  |e VerfasserIn  |0 (DE-588)1028286732  |0 (DE-627)730536823  |0 (DE-576)37578537X  |4 aut 
700 1 |a Moazen, Babak  |e VerfasserIn  |0 (DE-588)1160312494  |0 (DE-627)1023458780  |0 (DE-576)505837269  |4 aut 
773 0 8 |i Enthalten in  |t The lancet. Infectious diseases  |d New York, NY : Elsevier, 2001  |g 24(2024), 7, Seite 698-725  |h Online-Ressource  |w (DE-627)34191200X  |w (DE-600)2070985-7  |w (DE-576)121466701  |x 1474-4457  |7 nnas  |a Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy a systematic analysis for the Global Burden of Disease Study 2021 
773 1 8 |g volume:24  |g year:2024  |g number:7  |g pages:698-725  |g extent:28  |a Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy a systematic analysis for the Global Burden of Disease Study 2021 
856 4 0 |u https://doi.org/10.1016/S1473-3099(24)00007-0  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S1473309924000070  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20250313 
993 |a Article 
994 |a 2024 
998 |g 1160312494  |a Moazen, Babak  |m 1160312494:Moazen, Babak  |d 910000  |d 912800  |e 910000PM1160312494  |e 912800PM1160312494  |k 0/910000/  |k 1/910000/912800/  |p 272 
998 |g 1028286732  |a Jonas, Jost B.  |m 1028286732:Jonas, Jost B.  |d 60000  |e 60000PJ1028286732  |k 0/60000/  |p 202 
998 |g 127846140X  |a Al-Ahdal, Tareq  |m 127846140X:Al-Ahdal, Tareq  |d 50000  |e 50000PA127846140X  |k 0/50000/  |p 40 
999 |a KXP-PPN1919709061  |e 4686616115 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Online verfügbar: 19. März 2024, Artikelversion: 19. Juni 2024","Gesehen am 13.03.2025"],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"July 2024"}],"title":[{"subtitle":"a systematic analysis for the Global Burden of Disease Study 2021","title_sort":"Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy","title":"Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy"}],"id":{"eki":["1919709061"],"doi":["10.1016/S1473-3099(24)00007-0"]},"name":{"displayForm":["Jorge R. Ledesma, Tareq Mohammed Ali AL-Ahdal, Jost B Jonas, Babak Moazen [und andere]"]},"physDesc":[{"noteIll":"Illustrationen","extent":"28 S."}],"recId":"1919709061","relHost":[{"part":{"extent":"28","volume":"24","text":"24(2024), 7, Seite 698-725","issue":"7","year":"2024","pages":"698-725"},"titleAlt":[{"title":"The lancet <London> / Infectious diseases"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy a systematic analysis for the Global Burden of Disease Study 2021The lancet. Infectious diseases","title":[{"title":"The lancet","title_sort":"lancet","partname":"Infectious diseases"}],"origin":[{"publisherPlace":"New York, NY ; London","dateIssuedKey":"2001","publisher":"Elsevier ; Lancet Publ. Group","dateIssuedDisp":"2001-"}],"pubHistory":["1.2001 -"],"note":["Gesehen am 22.09.2021"],"id":{"eki":["34191200X"],"issn":["1474-4457"],"zdb":["2070985-7"]},"recId":"34191200X","physDesc":[{"extent":"Online-Ressource"}]}],"person":[{"role":"aut","given":"Jorge R.","family":"Ledesma","display":"Ledesma, Jorge R."},{"family":"Al-Ahdal","display":"Al-Ahdal, Tareq","given":"Tareq","role":"aut"},{"role":"aut","given":"Jost B.","display":"Jonas, Jost B.","family":"Jonas"},{"display":"Moazen, Babak","family":"Moazen","given":"Babak","role":"aut"}],"language":["eng"]} 
SRT |a LEDESMAJORGLOBALREGI2024